Document Type
Article
Publication Date
2-1-2013
Abstract
Propensity for developing coronary heart disease (CHD) is linked with Framingham-defined cardiovascular risk factors and elevated inflammatory biomarkers. Cardiovascular risk and inflammatory biomarkers were evaluated in ARIES, a Phase IIIb/IV clinical trial in which 515 antiretroviral-naive HIV-infected subjects initially received abacavir/lamivudine + atazanavir/ritonavir for 36 weeks. Subjects who were virologically suppressed by week 30 were randomized 1:1 at week 36 to either maintain or discontinue ritonavir for an additional 108 weeks. Framingham 10-year CHD risk scores (FRS) and risk category of
Recommended Citation
Young, Benjamin; Squires, Kathleen E; Ross, Lisa L; Santiago, Lizette; Sloan, Louis M; Zhao, Henry H; Wine, Brian C; Pakes, Gary E; Margolis, David A; and Shaefer, Mark S, "Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES." (2013). Division of Infectious Diseases and Environmental Medicine Faculty Papers. Paper 6.
https://jdc.jefferson.edu/didem/6
Comments
This article is the final published version in AIDS Research and Human Retroviruses Volume 29, Issue 2, March 2013, Pages 350-358.
The published version is available at DOI:10.1089/AID.2012.0278. Copyright © Mary Ann Liebert